Skip to main
GLUE

GLUE Stock Forecast & Price Target

GLUE Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 67%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Monte Rosa Therapeutics Inc demonstrates a robust financial outlook, highlighted by a projected enterprise value increase from $2.22 billion to $3.28 billion, signifying strong growth potential within its pipeline of molecular glue degraders (MGDs). The valuation of the NEK7-directed MGD, MRT-8102, has surged to $1.16 billion following positive interim Phase I trial data, reflecting investor confidence in the company's innovative strategies. Additionally, the anticipated year-end cash position has been revised upwards to $505 million, suggesting a solid financial foundation to support ongoing and future clinical developments.

Bears say

Monte Rosa Therapeutics Inc, a clinical-stage biotechnology company, is currently facing multiple challenges that contribute to a negative outlook on its stock. Key risks include potential setbacks in research and development, regulatory hurdles, and competition from emerging players in the biotechnology field, which may hinder the company's ability to advance its molecular glue degraders in clinical trials. Additionally, the recent denial of a related application by Novartis due to safety concerns raises questions about the viability of Monte Rosa's collaborations and the overall effectiveness of its therapeutic programs, potentially impacting future partnerships and revenue prospects.

GLUE has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 67% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Monte Rosa Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Monte Rosa Therapeutics (GLUE) Forecast

Analysts have given GLUE a Buy based on their latest research and market trends.

According to 3 analysts, GLUE has a Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $32, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $32, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Monte Rosa Therapeutics (GLUE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.